Hong Kong (HSI) Biotech Industry Analysis

Industry Valuation and Performance

Has the Hong Kong Biotech Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sat, 22 Aug 2026	HK$964.5b	HK$97.0b	-HK$1,018,040,710.32	26.2x	-947.4x	9.9x
Mon, 20 Jul 2026	HK$879.3b	HK$94.5b	-HK$4,119,595,524.12	19.6x	-213.4x	9.3x
Wed, 17 Jun 2026	HK$810.5b	HK$94.8b	-HK$4,484,573,436.80	17.6x	-180.7x	8.6x
Fri, 15 May 2026	HK$975.0b	HK$94.4b	-HK$3,924,423,524.48	22x	-248.4x	10.3x
Sun, 12 Apr 2026	HK$1.1t	HK$93.0b	-HK$3,924,201,229.43	29.3x	-278.4x	11.8x
Tue, 10 Mar 2026	HK$927.0b	HK$72.4b	-HK$11,897,209,181.25	48.9x	-77.9x	12.8x
Thu, 05 Feb 2026	HK$944.8b	HK$70.4b	-HK$14,009,022,252.67	33.8x	-67.4x	13.4x
Sat, 03 Jan 2026	HK$920.0b	HK$70.1b	-HK$13,848,895,501.12	35.8x	-66.4x	13.1x
Mon, 01 Dec 2025	HK$1.0t	HK$69.3b	-HK$12,920,525,774.10	41.4x	-81.1x	15.1x
Wed, 29 Oct 2025	HK$982.3b	HK$68.5b	-HK$13,143,538,086.78	44.9x	-74.7x	14.3x
Fri, 26 Sep 2025	HK$1.1t	HK$68.4b	-HK$13,333,128,226.15	48.4x	-83.3x	16.2x
Sun, 24 Aug 2025	HK$1.1t	HK$62.8b	-HK$13,590,104,940.08	57.8x	-81.6x	17.7x
Tue, 22 Jul 2025	HK$902.3b	HK$63.7b	-HK$12,197,903,611.90	39x	-74x	14.2x
Thu, 19 Jun 2025	HK$717.5b	HK$62.1b	-HK$11,770,540,029.51	34.5x	-61x	11.5x
Sat, 17 May 2025	HK$562.2b	HK$61.6b	-HK$11,850,892,393.57	30x	-47.4x	9.1x
Mon, 14 Apr 2025	HK$501.5b	HK$58.2b	-HK$10,846,605,463.11	26.2x	-46.2x	8.6x
Wed, 12 Mar 2025	HK$450.3b	HK$52.5b	-HK$16,891,468,306.53	21.9x	-26.7x	8.6x
Fri, 07 Feb 2025	HK$372.4b	HK$52.0b	-HK$17,287,227,526.18	13.2x	-21.5x	7.2x
Sun, 05 Jan 2025	HK$364.5b	HK$51.8b	-HK$17,195,281,172.77	11x	-21.2x	7x
Tue, 03 Dec 2024	HK$406.5b	HK$52.1b	-HK$17,313,921,660.76	10.8x	-23.5x	7.8x
Thu, 31 Oct 2024	HK$384.5b	HK$52.8b	-HK$17,770,538,198.25	11.3x	-21.6x	7.3x
Sat, 28 Sep 2024	HK$384.7b	HK$53.0b	-HK$18,430,711,177.10	11.9x	-20.9x	7.3x
Mon, 26 Aug 2024	HK$332.4b	HK$53.5b	-HK$18,888,703,785.07	11x	-17.6x	6.2x
Wed, 24 Jul 2024	HK$322.8b	HK$49.6b	-HK$19,418,195,713.85	12.3x	-16.6x	6.5x
Fri, 21 Jun 2024	HK$332.5b	HK$49.7b	-HK$19,448,990,522.83	11.4x	-17.1x	6.7x
Sun, 19 May 2024	HK$370.2b	HK$49.8b	-HK$19,398,952,876.68	12.1x	-19.1x	7.4x
Tue, 16 Apr 2024	HK$334.7b	HK$49.6b	-HK$19,903,440,471.84	11x	-16.8x	6.8x
Thu, 14 Mar 2024	HK$364.5b	HK$47.3b	-HK$20,348,874,667.32	17.8x	-17.9x	7.7x
Sat, 10 Feb 2024	HK$322.5b	HK$46.8b	-HK$20,190,080,935.32	15.6x	-16x	6.9x
Mon, 08 Jan 2024	HK$376.7b	HK$47.0b	-HK$20,300,331,811.00	16.9x	-18.6x	8x
Wed, 06 Dec 2023	HK$413.2b	HK$47.0b	-HK$20,307,662,700.00	18.4x	-20.3x	8.8x
Fri, 03 Nov 2023	HK$414.7b	HK$45.1b	-HK$18,893,824,560.00	13x	-21.9x	9.2x
Sun, 01 Oct 2023	HK$400.6b	HK$45.0b	-HK$19,138,973,954.00	13.9x	-20.9x	8.9x
Tue, 29 Aug 2023	HK$383.9b	HK$39.2b	-HK$20,777,976,857.00	16.1x	-18.5x	9.8x

Current Industry PE

Investors are relatively neutral on the Hong Kong Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.

The industry is trading close to its 3-year average PS ratio of 9.9x.

Past Earnings Growth

The earnings for companies in the Biotechs industry have improved over the last three years.
Revenues for these companies have grown 35% per year.
This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare industry?


HK Market	3.64%
Healthcare	3.72%
Biotech	1.04%
Biotech	1.04%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
1801 Innovent Biologics	HK$102.40	9.2% +HK$15.0b	3.0%	PE187.9x
6990 Sichuan Kelun-Biotech Biopharmaceutical	HK$538.00	3.4% +HK$4.2b	15.3%	PE729.2x
7666 Metis TechBio	HK$14.24	17.6% +HK$2.5b	n/a	PS137.5x
6185 CanSino Biologics	HK$29.48	19.4% +HK$1.2b	-43.1%	PS5.6x
2595 GenFleet Therapeutics (Shanghai)	HK$33.92	10.0% +HK$1.1b	n/a	PS82.7x

Company

Last Price

Valuation

1801 Innovent Biologics

HK$102.40

9.2%
+HK$15.0b

3.0%

PE187.9x

6990 Sichuan Kelun-Biotech Biopharmaceutical

HK$538.00

3.4%
+HK$4.2b

15.3%

PE729.2x

7666 Metis TechBio

HK$14.24

17.6%
+HK$2.5b

n/a

PS137.5x

6185 CanSino Biologics

HK$29.48

19.4%
+HK$1.2b

-43.1%

PS5.6x

2595 GenFleet Therapeutics (Shanghai)

HK$33.92

10.0%
+HK$1.1b

n/a

PS82.7x

Akeso Receives Clinical Trial Clearance For AK157D1 B7-H3 Antibody-Drug Conjugate In Solid Tumors

Akeso, Inc. announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The clearance allows initiation of a Phase I study in patients with advanced malignant solid tumors. Development of AK157D1 in combination with Akeso's proprietary bispecific antibodies ivonescimab and cadonilimab is also planned. AK157D1 is the third next-generation ADC candidate from Akeso to enter clinical development, following AK146D1 (TROP2/Nectin-4 ADC) and AK138D1 (HER3 ADC). The clearance further advances the Company's IO2.0 + ADC2.0 strategy and expands its broad innovative oncology pipeline. B7-H3 is highly expressed in a broad range of solid tumors, including non-small cell lung cancer, small cell lung cancer, prostate cancer, esophageal cancer, nasopharyngeal carcinoma, colorectal cancer, breast cancer, and glioblastoma, with limited expression in normal tissues. This profile supports its potential as a broad-spectrum antitumor target. AK157D1 was developed entirely in-house and incorporates a proprietary design. In preclinical studies, it has shown potent antitumor activity together with a favorable safety profile. These attributes may help address certain limitations associated with existing ADCs, including hematologic toxicity and interstitial lung disease, and support its continued development as a potential ADC of choice in both mono or combination therapies. Akeso is advancing its IO2.0 + ADC2.0 strategy, built on proprietary bispecific and multispecific antibody technology and centered on cornerstone IO2.0 assets including ivonescimab and cadonilimab. In the immuno-oncology field, Akeso has two approved bispecific antibodies for cancer treatment. The Company is actively evaluating ivonescimab and cadonilimab in combination with its proprietary next-generation ADC candidates. In the ADC space, Akeso has built a differentiated pipeline of next-generation candidates, including AK146D1 and AK138D1, which are already in clinical development, and AK157D1 and AK158D1 (a bispecific ADC), which are anticipated to enter the clinic shortly. These agents are designed to address the narrow therapeutic window and safety limitations commonly associated with first-generation ADCs. AK157D1 is a novel B7-H3-targeting ADC independently developed by Akeso. It comprises a recombinant humanized IgG1/? monoclonal antibody site-specifically conjugated to Dxd, a camptothecin-derived topoisomerase I inhibitor, via a maleimidocaproyl-alanine-alanine-alanine (MC-AAA) linker to interchain cysteine residues. Preclinical studies have demonstrated potent antitumor activity and a favorable safety profile.

Hong Kong (HSI) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Akeso Receives Clinical Trial Clearance For AK157D1 B7-H3 Antibody-Drug Conjugate In Solid Tumors

Ascentage Pharma Appoints Two Senior Executives and Advances Nine Global Phase III Trials

First half 2026 earnings released: EPS: CN¥0.45 (vs CN¥0.57 in 1H 2025)

New minor risk - Share price stability

CARsgen Wins NMPA Approval for First CAR-T Therapy in Solid Tumors and Reports Pipeline Advances

Earnings Update: Here's Why Analysts Just Lifted Their Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Price Target To HK$612

InnoCare Pharma Wins Approval for Phase III Trial of Mesutoclax Versus Venetoclax in AML

Harbour BioMed Receives NMPA IND Approval for HBM7004 in Advanced Tumor Therapy

New major risk - Revenue and earnings growth

Metis TechBio Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026

Innovent Biologics, Inc. to Report First Half, 2026 Results on Aug 25, 2026

Investor sentiment improves as stock rises 15%

Innogen Pharmaceuticals Receives PIC/S GMP Certification from Anvisa for Efsubaglutide Alfa Manufacturing Facility

Investor sentiment improves as stock rises 19%

GenFleet Therapeutics (Shanghai) Inc. has filed a Follow-on Equity Offering in the amount of HKD 471.784 million.

Investor sentiment improves as stock rises 22%